source
- Capricor Therapeutics receives second FDA rejection for Duchenne cell therapy deramiocelThe U.S. Food and Drug Administration issued a second complete response letter rejecting Capricor Therapeutics' cell therapy deramiocel for Duchenne muscular dystrophy. The agency said the data did…
- FDA rejects Capricor's Duchenne cell therapy again, citing major trial flawsCapricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy was denied by the FDA for a second time. The agency highlighted significant issues with the trial design and data, le…